What Is the Best Painkiller for Shingles?

There is no single “best” painkiller for shingles because the pain shifts character as the disease progresses, and different drugs target different mechanisms. During the acute rash, antivirals paired with conventional analgesics do most of the heavy lifting. Once the rash heals, the pain that lingers, known as postherpetic neuralgia, is nerve-driven and responds best to drugs originally developed for epilepsy or depression. The practical answer is a staged approach: start with antivirals and simple pain relief early, then escalate to neuropathic-specific medications if pain persists.

Antivirals Are the Foundation, Not Just Antiviral Drugs

It sounds counterintuitive to call an antiviral the first step in pain management, but the virus itself is the engine of shingles pain. Valacyclovir, acyclovir, and famciclovir shorten the acute episode and reduce the chances of developing long-lasting nerve pain. One randomized trial comparing an investigational antiviral (FV-100) against valacyclovir found that roughly one in five patients on valacyclovir still developed postherpetic neuralgia, with a trend toward even lower rates in the experimental drug arms, suggesting that more potent viral suppression could translate into less pain down the line.¹

Even after the acute phase, antivirals may still help. A randomized trial in patients with shingles affecting the eye found that low-dose valacyclovir shortened the overall duration of pain by roughly three months compared with placebo at the 18-month mark.² The takeaway is straightforward: if you have a shingles rash, get antivirals within 72 hours of onset. They are the closest thing to a pain-prevention strategy the evidence supports.

Pregabalin and Gabapentin for Nerve Pain

Once shingles pain becomes nerve pain, whether during the rash or after it clears, gabapentinoids are the most commonly prescribed first-line painkillers. These drugs calm overexcited nerve signals and are specifically designed for neuropathic pain. Gabapentin has been used for decades, and pregabalin is its newer, more refined sibling. The question patients and doctors wrestle with is which one to pick.

A meta-analysis pooling data from randomized trials found that pregabalin was better than gabapentin at reducing pain intensity, improving sleep, and achieving a positive overall impression of change in patients with postherpetic neuralgia. However, gabapentin had fewer side effects and a better safety profile.³ A broader systematic review covering neuropathic pain in general confirmed these findings: pregabalin produced lower pain scores on standard scales, more days with no or mild pain, and fewer days with severe pain over a 12- to 14-week period.⁴

One study that switched postherpetic neuralgia patients from gabapentin to pregabalin suggested that pregabalin’s pain-relieving effect was about six times stronger on a milligram-for-milligram basis.⁵ That does not mean pregabalin is always the right choice. It tends to cause more dizziness and drowsiness, which can be a real problem for older adults already at risk of falls. Many doctors start with gabapentin because it is cheaper and better tolerated, then switch to pregabalin if pain relief is insufficient. Both drugs need gradual dose increases over days to weeks, and neither works instantly.

Antidepressants That Double as Painkillers

Tricyclic antidepressants, particularly amitriptyline and nortriptyline, are another first-line option for postherpetic neuralgia. They work through a different mechanism than gabapentinoids, dampening pain signals by boosting certain brain chemicals involved in the body’s own pain-suppression pathways. There is preliminary evidence that starting low-dose amitriptyline during the acute shingles phase might even prevent postherpetic neuralgia from developing, though this has only been suggested by one small trial and better evidence is actively being sought through a dedicated study called ATHENA.⁶

The main drawback of tricyclics is their side effect profile. Dry mouth, constipation, blurred vision, drowsiness, and a risk of heart rhythm changes make them particularly tricky in older patients, who also happen to be the group most likely to get shingles. Because of these cardiac concerns, doctors typically order an electrocardiogram before starting a tricyclic in anyone over 60 or with heart disease. Nortriptyline tends to be slightly better tolerated than amitriptyline but has somewhat less pain data behind it.

Topical Treatments That Stay Local

For people who want to avoid the brain fog and dizziness of systemic drugs, topical options offer targeted relief. The two main players are lidocaine patches and high-concentration capsaicin patches, and they work in very different ways.

Lidocaine patches numb the skin by blocking nerve signals right at the surface. A double-blind trial in patients with active shingles rashes found that lidocaine patches reduced pain during both rest and movement compared with placebo patches, with patients reporting a noticeably better global impression of their pain control. Side effects were minimal.⁷ These patches are applied directly over the painful area for up to 12 hours at a time and can be used alongside oral medications without significant drug interactions, which makes them a useful add-on rather than a stand-alone solution for severe pain.

Capsaicin patches take a more aggressive approach. The high-concentration 8% capsaicin patch is applied for 60 minutes in a clinical setting and works by overwhelming and then desensitizing the very nerve fibers that transmit pain. A single application can provide relief lasting up to three months, and the treatment can be repeated if pain returns.⁸ The catch is that the application itself can be intensely painful, with burning, redness, and swelling at the site. Most patients find these effects tolerable and temporary, but you need to go through a brief spike in discomfort before the longer-term benefit kicks in.

Opioids and Corticosteroids

Opioids like oxycodone and tramadol are generally reserved for shingles pain that does not respond to first-line treatments. They can be effective: research has shown that patients taking oxycodone were significantly more likely to experience meaningful pain reduction compared with placebo. But tolerability is a major problem. Constipation, nausea, and sedation drive high dropout rates, and the risk of dependence makes doctors reluctant to prescribe opioids for longer than a few weeks. When they are used, it is usually as a short bridge while neuropathic medications are titrated up to therapeutic doses.

Corticosteroids like prednisone are sometimes added during the acute phase to reduce inflammation and swelling. A trial comparing low, medium, and high doses of prednisone in shingles patients found that while the drug helped with acute symptoms, the incidence of postherpetic neuralgia was essentially the same across all dose groups, hovering around 15%.⁹ In other words, steroids can make you more comfortable during the rash but do not appear to prevent ongoing nerve pain afterward. Their use is usually limited to a short tapering course.

Nerve Blocks and Interventional Procedures

For patients whose pain is severe or unresponsive to medications, interventional procedures offer another avenue. These involve injecting local anesthetics or steroids near the nerves responsible for the pain. A systematic review and meta-analysis found that not all nerve blocks are equally effective. Single epidural injections and stellate ganglion blocks did not reduce the chance of developing postherpetic neuralgia, but paravertebral blocks and continuous or repeated epidural injections did lower the incidence at three months.¹⁰

A patient-centered study tracking pain scores before and after interventional pain management found that scores dropped dramatically, from a median of 8 out of 10 down to 3 in shingles patients, and from 5 down to 2 in those with established postherpetic neuralgia.¹¹ These procedures are not first-line treatments, but they are worth knowing about if oral and topical medications are not cutting it.

Non-Drug Approaches Worth Considering

Transcutaneous electrical nerve stimulation, or TENS, uses small adhesive electrodes to deliver mild electrical pulses through the skin. The idea is that these pulses interfere with pain signals before they reach the brain. TENS has the advantage of being non-invasive and carrying essentially no risk of the drug interactions or toxicities that plague systemic painkillers, making it a useful supplement for people already taking multiple medications.¹² The evidence for TENS in shingles specifically is still building, but it is a low-risk option that some patients find helpful as an add-on.

Acupuncture has generated a fair amount of research in the shingles space. A systematic review and meta-analysis of 22 studies found that acupuncture showed advantages over control treatments in pain reduction, time to skin healing, and lower rates of postherpetic neuralgia, with a lower risk of side effects compared with Western medication alone.¹³ A separate meta-analysis focused specifically on postherpetic neuralgia found that acupuncture reduced pain intensity and anxiety while improving quality of life, rating the quality of pain-intensity evidence as moderate.¹⁴ The caveat with acupuncture research is that many of the underlying trials come from settings where blinding is difficult, and publication bias is a concern. Still, for patients interested in non-pharmacological options, the evidence is more supportive than dismissive.

Cognitive behavioral therapy deserves mention as well. A pilot study combining CBT with pregabalin in postherpetic neuralgia patients found significant improvements in pain intensity, burning sensations, and catastrophizing thoughts about pain. Depressive symptoms and overall quality of life also improved.¹⁵ This makes intuitive sense: chronic pain is not just a nerve signal, it is also shaped by how your brain interprets and reacts to that signal. Addressing the psychological dimension alongside the pharmacological one gives patients more tools.

Why Timing and Escalation Matter More Than Picking One Drug

The biggest mistake people make with shingles pain is waiting too long to treat it or assuming one medication should do all the work. Shingles pain has multiple overlapping causes: active viral damage, inflammation, and nerve sensitization. No single drug addresses all three. The practical strategy is layered. Start antivirals immediately. Add simple analgesics like acetaminophen or ibuprofen for the acute phase. If pain is clearly nerve-driven, which it usually is from the start in shingles, begin a gabapentinoid or tricyclic early. Layer on a topical like lidocaine if the pain is localized and you want to minimize systemic side effects. Reserve opioids for breakthrough pain only, and consider interventional procedures if weeks of oral therapy are not producing adequate relief.

Older adults need particular attention in this escalation. They are simultaneously the most likely to develop severe postherpetic neuralgia and the most vulnerable to the side effects of every drug used to treat it. Gabapentinoids cause dizziness and drowsiness, tricyclics affect the heart and bladder, and opioids cause falls and confusion. Topicals become especially valuable in this population precisely because they bypass most of those systemic risks. Dose adjustments and slow titration schedules are not optional in patients over 65; they are essential.¹⁶

Investigational Drugs on the Horizon

The current toolkit, while effective for many patients, leaves a significant minority with inadequately controlled pain. Researchers are looking at new pharmacological targets. One example is funapide, a topical drug that blocks specific sodium channels involved in nerve pain signaling. A Phase II trial in postherpetic neuralgia tested this approach and, while the overall group did not reach a statistically significant improvement, a subgroup of patients with a particular genetic variation in one of the targeted sodium channels did achieve meaningful pain reduction.¹⁷ This kind of finding hints at a future where pain treatment could be personalized based on genetic testing, identifying which specific nerve channels are driving each patient’s pain and choosing drugs accordingly.

Other investigational approaches include antibodies targeting nerve growth factor, TRPV1 receptor modulators, and novel formulations of existing drugs designed to improve absorption through the skin. None of these are available yet outside of clinical trials, but they reflect a growing recognition that postherpetic neuralgia is not a single disease with a single solution. The next generation of shingles painkillers will likely be more targeted than anything we have now.

The Hidden Cost of Undertreated Pain

Shingles pain is not just uncomfortable; it reshapes daily life. A study tracking quality of life in shingles patients found that pain lowered overall health scores by an average of 18%, and that the presence of pain was a major driver of increased healthcare costs.¹⁸ Population-level analyses of shingles costs have noted that direct medical expenses capture only part of the burden. Lost productivity, disability, caregiver time, and opportunity costs all add up but are rarely measured in formal studies.¹⁹

This matters for a practical reason: patients sometimes hesitate to escalate treatment because they assume shingles pain will just go away on its own. For some it does. But postherpetic neuralgia can persist for months or years, and undertreating it in the early weeks can set up patterns of chronic pain that are harder to break later. The evidence consistently supports aggressive early management. If your first painkiller is not working, the answer is not patience. It is a conversation with your doctor about adding or switching to something that targets the nerve component of the pain.

Prevention Through Vaccination

The most effective pain strategy is avoiding shingles altogether. The recombinant zoster vaccine (Shingrix) reduces the risk of shingles by more than 90% in adults over 50 and remains highly effective in adults over 70. Because postherpetic neuralgia only develops after a shingles episode, preventing the episode eliminates the risk entirely. Serious adverse events from the vaccine are exceedingly rare. A report on post-vaccine neuropathy estimated the attributable risk at roughly three cases per million doses administered.²⁰ For anyone over 50 who has not been vaccinated, getting the shot is a far simpler proposition than navigating the multi-drug, multi-month pain management pathway described above.